Revance to Participate in Upcoming Investor Conferences
May 31 2016 - 4:05PM
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and
therapeutic indications, today announced that the company will
participate in two upcoming investor conferences.
Revance management is scheduled to present at the Jefferies 2016
Global Healthcare Conference in New York, NY on Tuesday, June 7 at
11:30am ET.
Revance management is also scheduled for a fireside chat at the
William Blair 36th Annual Growth Stock Conference in Chicago,
IL on Tuesday, June 14 at 10:10am CT.
Interested parties can access the live audio webcast for both of
these conferences from the Investor Relations section of the
company's website at www.revance.com. The webcast replay will
be available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc. Revance,
a Silicon Valley-based biotechnology company, is committed to the
advancement of remarkable science. The company is developing
a portfolio of products for aesthetic medicine and underserved
therapeutic specialties, including neurology. Revance’s
trajectory to commercial success begins with the company’s novel
and proprietary TransMTS® carrier-peptide delivery system, which is
uniquely designed to target and transport macromolecules to their
desired location.
Revance’s journey to market starts with the neurotoxin
daxibotulinumtoxinA, the company’s highly purified botulinum toxin
type A. The TransMTS technology is used in the delivery of
botulinum toxin through two novel drug product candidates:
DaxibotulinumtoxinA Topical Gel (RT001) that permits needle-free
application, and DaxibotulinumtoxinA for Injection (RT002), which
is designed to enable targeted administration and long-lasting
effect.
Revance is developing RT001 and RT002 for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles,
excessive sweating and muscle movement disorders. The company
holds worldwide rights for all indications of RT001, RT002, and the
TransMTS technology platform. Beyond botulinum toxin,
Revance believes the TransMTS technology can be applied to
transdermal, mid-dermal or deep tissue delivery of a variety of
other macromolecules. More information on Revance can be
found at www.revance.com.
"Revance Therapeutics", TransMTS®, “Remarkable Science Changes
Everything”, and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
Contacts
Investors:
Revance Therapeutics
Jeanie Herbert
(714) 325-3584
jherbert@revance.com
Burns McClellan
Ami Bavishi
(212) 213-0006
abavishi@burnsmc.com
Trade Media:
Nadine Tosk
(504) 453-8344
nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024